Novo Nordisk licenses Nanexa depot platform in deal worth up to €1.17 billion

The wire

1. 01Novo gets exclusive worldwide rights across up to five programs; Nanexa could collect up to €615 million in upfront, development and regulatory milestones plus €550 million in sales milestones.
2. 02Long-acting formulation work puts Novo alongside Eli Lilly and Pfizer as the incretin field moves past weekly injections and toward oral options.
3. 03Shares rose 0.3% to EUR 34.03 on the news and are down 23% year to date; a Jyske Bank analyst called the deal modest relative to Novo's scale.

From the source

Novo Nordisk Spends Big on Monthly Shots While EMA Backs Two New Therapies

Novo Nordisk is attacking its pipeline problem from both ends of the calendar. On one front, the Danish drugmaker has secured a technology that could stretch injection intervals from a week to a month or even a quarter. On another, European regulators have just endorsed two therapies that have nothing to do with obesity. Investors, so far, are unmoved.